Project: New drug combination therapy for pancreatic cancer treatment: a disruptive multifaceted approach
| Acronym | IMMUNORESIST (Reference Number: 115466) |
| Duration | 01/10/2021 - 01/10/2023 |
| Project Topic | IMMUNORESIST aims at seizing a major market opportunity by developing SCO-101 and Mitazalimab, a new combination therapy (CT) that targets chemotherapy resistance in pancreatic cancer (PC) treatment, while boosting the patient’s immune system. We will deliver a CT treatment that is preclinically validated, has confirmed safety in humans, and is ready to enter Phase 1b clinical trials (dose escalation studies), evaluating CT safety and tolerability (Fig 1, Annex). |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Alligator Bioscience AB | Partner | Sweden |
| 2 | Scandion Oncology A/S | Coordinator | Denmark |
| 3 | University of Southern Denmark | Partner | Denmark |